Quotient Sciences Strengthens Its Top Team with Three New Appointments

March 18, 2024

Quotient Sciences Strengthens Its Top Team with Three New Appointments

NOTTINGHAM, UK; 18 March 2024 – Drug development and manufacturing accelerator Quotient
Sciences has announced major changes to its commercial and scientific executive leadership team,
strengthening its position as a global leader in the sector.

New appointments include Dr. Andrew Lewis as Chief Scientific Officer, Kieron Hall as Chief
Marketing Officer, and Eric Bironneau as Chief Business Officer who will each play a critical role in
Quotient Sciences growth and strategic direction.

In his new role as Chief Scientific Officer, Dr. Andrew Lewis has responsibility for the company’s
scientific and technological innovation. Andrew will lead the team of Drug Development Consultants
and Scientific Research Fellows to grow Quotient Sciences’ global scientific expertise and recognition.
During his eight years with Quotient Sciences, Andrew has held various scientific leadership
positions, most recently as Senior Vice President, Pharmaceutical Development. Prior to joining
Quotient Sciences, Andrew was Director of Novel Drug Delivery Technologies at Ipsen.

Kieron Hall’s appointment as Chief Marketing Officer will see him lead the company’s strategic and
growth initiatives and marketing organization. Kieron has been with the company in various global
commercial leadership positions for more than 16 years, including Chief Commercial Officer. He was
Head of Business Development in Europe for Cyprotex (an Evotec company) before joining Quotient

Eric Bironneau has joined the company as Chief Business Officer, with responsibility for Quotient
Sciences’ commercial organization across drug substance, drug product, and Translational
Pharmaceutics® commercial lines, as well as for Quotient Sciences’ strategic partnerships. Eric
brings over two decades of commercial leadership experience to the company, including serving as
Vice President, Global Sales & Business Development at Axplora and Novasep.

These latest changes come off the back of Thierry Van Nieuwenhove joining the company as CEO last
October succeeding their long-standing leader Mark Egerton, who retired after 18 years with the

“We are committed to continuing our strategy of accelerating drug development, bringing new
medicines to patients faster by breaking down traditional industry silos and leading with a science-
first mindset for how we deliver customer programs,” said Thierry Van Nieuwenhove, CEO of
Quotient Sciences. “I am excited to work with Andrew, Kieron, and Eric in their new roles, along with
the rest of our leadership team, to continue to grow Quotient Sciences as a global leader in drug


About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated
programs and tailored services across the entire development pathway. Cutting through silos across
a range of drug development capabilities, we save precious time and money in getting drugs to
patients. Everything we do for our customers is driven by an unswerving belief that ideas need to
become solutions, and molecules need to become cures, fast. Because humanity needs solutions,
Quotient Sciences Company Contact

ramarketing contact
Rachael Heath